Elisabeth Krones

Medicine · Health Sciences

18h-index1.5kcitations64works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver Disease Diagnosis and Treatment(30), Liver Disease and Transplantation(25), Liver Diseases and Immunity(10), Pediatric Hepatobiliary Diseases and Treatments(8), Drug Transport and Resistance Mechanisms(6)

Publications63 total

Variants in <i>PCSK7, PNPLA3</i> and <i>TM6SF2</i> are risk factors for the development of cirrhosis in hereditary haemochromatosis
Alimentary Pharmacology & Therapeutics·2021· 12 citedOpen Access
Changes in the Intestinal Microbiome during a Multispecies Probiotic Intervention in Compensated Cirrhosis
Nutrients·2020· 49 citedOpen Access
FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis
Journal of Hepatology·2020· 69 cited
The modulation of the gut microbiome during a multispecies probiotic intervention in compensated cirrhosis
Zeitschrift für Gastroenterologie·2019
SAT-048-Changes in the intestinal microbiome during probiotic intervention in cirrhosis
Journal of Hepatology·2019· 1 cited
Future Medical Treatment of PSC
Current Hepatology Reports·2019· 8 citedOpen Access
Clinical-Pathological Conference Series from the Medical University of Graz
Wiener klinische Wochenschrift·2018Open Access
Functional response of neutrophils is associated with serum bile acids profile in liver cirrhotic patients
Zeitschrift für Gastroenterologie·2018
Changes of bile acids profile in different etiologies of liver cirrhosis and its association with neutrophil response
Journal of Hepatology·2018
Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology
Case Reports in Oncology·2017· 3 citedOpen Access
Ultrasound verified inflammation and structural damage in patients with hereditary haemochromatosis-related arthropathy
Arthritis Research & Therapy·2017· 17 citedOpen Access
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III)
Wiener klinische Wochenschrift·2017· 134 citedOpen Access
Cholemic nephropathy – Historical notes and novel perspectives
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease·2017· 64 cited
Genetic loss of the muscarinic M<sub>3</sub> receptor markedly alters bile formation and cholestatic liver injury in mice
Hepatology Research·2017· 11 citedOpen Access
Renal dysfunction in cirrhosis: acute kidney injury and the hepatorenal syndrome
Gastroenterology report·2017· 104 citedOpen Access
NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice
Journal of Hepatology·2017· 65 cited
Exercise capacity and exercise hemodynamics in the screening for pulmonary vascular disease (PVD) in patients with portal hypertension – results from a prospective cross-sectional study
Journal of Hepatology·2017
Macrophage activation markers sCD163 and mannose receptor predict survival and correlate with markers of gut permeability in patients with liver cirrhosis
Journal of Hepatology·2017
Intestinal colonisation by Veillonella spp. is predictive for mortality in stable cirrhosis and could be partially reduced by a multispecies probiotic in a randomized placebo controlled trial
Journal of Hepatology·2017· 1 cited
Table of contents
Hepatology·2016Open Access
page 1 of 4Next →

Frequent Co-authors

Peter Fickert(37), Franziska Durchschein(23), Gernot Zollner(22), Vanessa Stadlbauer(18), Michael Trauner(16), Philipp Douschan(15), Bettina Leber(12), Philipp Stiegler(12), Walter Spindelboeck(11), Marion J. Pollheimer(10), Florian Rainer(9), R.E. Stauber(9), Angela Horvath(8), Emina Halilbasic(7), Rudolf Stauber(7), Tarek Moustafa(6), Alexander R. Rosenkranz(6), B. Schmerboeck(6), Sandra Lemesch(6), Anna Baghdasaryan(5)